Clinical Trials Directory

This study has two groups, and you will have an equal chance of being in either one. In Group 1, people get the usual treatment for advanced prostate cancer. This includes hormonal therapy, which can be given as a shot or as pills, and apalutamide, which is taken as four pills once a day. In Group 2, people get a chemotherapy drug called docetaxel along with the usual hormonal therapy and apalutamide. Docetaxel is given through a vein every three weeks for up to six doses. People in this group also get steroids through an IV on the day they receive docetaxel to help reduce side effects.

We are doing this study to compare two different treatment options for mantle cell lymphoma. We want to find out which option has the best outcomes for older adults. We will compare the results of continuous treatment with zanubritinib to treatment with zanubrutinib that is stopped after the initial six 28-day cycles of chemotherapy and restarted only if your disease gets worse following the initial six 28-day cycles of chemotherapy.

We are doing this study to help create a national biobank of samples and data about patients who experience side effects when they take immunotherapy drugs for their cancer. We want to find out why some people experience side effects and why others do not. We also want to learn more about how to diagnose and treat these side effects more effectively.

We are doing this study to test a new strategy to help people quit smoking. We want to know if the study approach is better than the usual approach. The usual approach is to encourage patients to quit smoking using cessation support manuals and either medication or nicotine replacement products. We want to know if the study approach works better for cancer survivors who live in rural areas.

We are doing this study to see if the study drugs ABBV-400 and budigalimab, in combination with chemotherapy, are a safe and effective option for treating gastroesophageal cancer. We are also trying to find the best dose of ABBV-400 to use.

People in this study will be in one of two groups. One group will get a medicine called ABBV-400 through an IV every 21 days. The other group will not get medicine but will have blood tests for cancer DNA and imaging scans to check for cancer.

What happens in this study? - You'll get the study medicine through an IV every 3 weeks - Depending on your group, you might also get: - Budigalimab (a new medicine being tested) - Or a standard cancer medicine - You'll give blood and urine samples - You'll have regular CT or MRI scans to check your health